Drug Profile

CM 355

Alternative Names: CM355; ICP-B02

Latest Information Update: 28 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator InnoCare Pharma; KeyMed Biosciences
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II B-cell lymphoma

Most Recent Events

20 Jan 2025 CM 355 licensed to Prolium Bioscience outside of Asia .
14 Jun 2024 Efficacy and adverse events data from the phase I/II trial in B-cell lymphoma released by InnoCare
13 Jun 2024 Interim adverse events, efficacy and pharmacokinetics data from a phase-I/II trial in B-cell lymphoma presented at the 29^th Congress of the European Haematology Association (EHA-2024) ,

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com